Dual-listed biotech Mesoblast (ASX:MSB) has announced that chair Jane Bell will retire from the role and continue as a non-executive director, as part of a board reshuffle following a regular governance review.
The board has unanimously appointed Philip Facchina as non-executive chair, with Lyn Cobley named chair of the audit and risk committee, while William Burns will remain vice-chair and continue to lead the nomination and remuneration committee.
Facchina, who joined the Mesoblast board in March 2021, said the company was "deeply grateful" to Bell for her leadership during a critical transition from development to commercialisation.
Cobley was appointed to the board in April 2025, and Mesoblast said it expects to further strengthen its US commercial expertise over the next 12 months.
At the time of reporting, Mesoblast's share price was $2.78.